FDA Lifts Clinical Hold On Sarepta's Dose-Expansion Part Of Duchenne Trial
The FDA has removed the clinical hold on Sarepta Therapeutics Inc's (NASDAQ: SRPT) SRP-5051 (vesleteplirsen) for Duchenne muscular dystrophy who are amenable to exon 51 skipping.
After discussions with FDA and as part of the lift, Sarepta will adjust the global trial protocol to include expanded monitoring of urine biomarkers.
Also Read: Sarepta Reports One Heart Inflammation Case In Duchenne Gene Therapy Trial.
The hold in Part B of Study 5051-201, also known as MOMENTUM, followed a serious adverse event of hypomagnesemia (magnesium deficiency). The company provided information to FDA to assess the adequacy of the risk mitigation and safety monitoring plan.
MOMENTUM Phase 2 trial has continued enrolling participants outside the U.S., and the company remains on track to complete enrollment by the end of 2022.
Price Action: SRPT shares are up 0.13% at $109.52 during the premarket session on the last check Tuesday.
See more from Benzinga
Ironwood's Constipation Drug Shows Efficacy In Pediatric Patients
FDA Might Need New Data From Eiger Bio's COVID-19 Treatment Prospect
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.